RespirologyVolume 26, Issue S3 p. 176-176 AbstractFree Access P5-50: Withdrawn First published: 19 November 2021 https://doi.org/10.1111/resp.14150_257AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text full-text accessPlease review our Terms and Conditions of Use check box below share version article.I have read accept the Wiley O...

In the phase III DESTINY-Breast04 trial (NCT03734029), T-DXd significantly improved progression-free survival (PFS) and overall (OS) vs TPC in pts with HER2-low mBC regardless of hormone receptor expression. Breast cancers low ER expression (IHC 1-10%) represent a subset that may mimic clinical behavior triple-negative breast cancer. Here, we report analyses IHC 0% 1-10%. Pts (HER2 1+ or 2+/ISH...